OncUView.tv - Video Library - Oncology News and Information for Healthcare Professionals > Nilotinib Versus Imatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive CML-CP — interview with Giuseppe Saglio, MD, at ASH 2011

Install latest flash player if this video gallery doesn't work.

Nilotinib Versus Imatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive CML-CP — interview with Giuseppe Saglio, MD, at ASH 2011
At the American Society of Hematology (ASH) 2011, Giuseppe (Beppe) Saglio, MD, Professor of Internal Medicine and Hematology, and Director of the Department of Molecular Medicine and Targeted Therapy at the San Luigi Hospital, University of Turin, Italy, discusses ENESTnd, nilotinib versus imatinib in CML-CP, a 36-month follow-up. Accompanying this interview is a downloadable copy of the abstract.